Orient Europharma Co., Ltd. Statistics
Orient Europharma Co., Ltd. (4120) Stock Statistics & Valuation Metrics
Total Valuation
Orient Europharma Co., Ltd. has a market cap or net worth of TWD 3.67B. The enterprise value is TWD 6.92B.
- Market Cap
- TWD 3.67B
- Enterprise Value
- TWD 6.92B
Share Statistics
Orient Europharma Co., Ltd. has 86,747,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 86,747,120
- Owned by Insiders
- ―
- Owned by Institutions
- 0.02%
Financial Efficiency
Orient Europharma Co., Ltd.’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -2.74%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -2.74%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 13.55M
- Profits Per Employee
- -1.67M
- Employee Count
- 339
- Asset Turnover
- 0.38
- Inventory Turnover
- 2.30
Valuation Ratios
The current PE Ratio of Orient Europharma Co., Ltd. is -6.32. Orient Europharma Co., Ltd.’s PEG ratio is 0.10.
- PE Ratio
- -6.32
- PS Ratio
- 0.78
- PB Ratio
- 0.70
- Price to FCF
- -4.42
- Price to Operating Cash Flow
- -6.09
- PEG Ratio
- 0.10
Income Statement
In the last 12 months, Orient Europharma Co., Ltd. had revenue of 4.60B and earned -567.39M in profits. Earnings per share was -6.54.
- Revenue
- 4.60B
- Gross Profit
- 2.10B
- Operating Income
- -310.54M
- Pretax Income
- -273.03M
- Net Income
- -567.39M
- EBITDA
- -121.76M
- Earnings Per Share (EPS)
- -6.54
Cash Flow
In the last 12 months, operating cash flow was -598.50M and capital expenditures -227.11M, giving a free cash flow of -825.61M billion.
- Operating Cash Flow
- -598.50M
- Free Cash Flow
- -825.61M
- Free Cash Flow per Share
- -9.52
Dividends & Yields
Orient Europharma Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 9.46%
- Dividend Per Share
- ―
- Dividend Yield
- 9.46%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.63%
- Earnings Yield
- -14.76%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -9.52%
- 50-Day Moving Average
- 45.50
- 200-Day Moving Average
- 43.74
- Relative Strength Index (RSI)
- 24.25
- Average Volume (3m)
- 21.88K
Important Dates
Orient Europharma Co., Ltd. upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Orient Europharma Co., Ltd. as a current ratio of 1.47, with Debt / Equity ratio of 52.00%
- Current Ratio
- 1.47
- Quick Ratio
- 1.10
- Debt to Market Cap
- 0.76
- Net Debt to EBITDA
- -10.54
- Interest Coverage Ratio
- -4.19
Taxes
In the past 12 months, Orient Europharma Co., Ltd. has paid 207.16M in taxes.
- Income Tax
- 207.16M
- Effective Tax Rate
- -0.76
Enterprise Valuation
Orient Europharma Co., Ltd. EV to EBITDA ratio is -38.60, with an EV/FCF ratio of -6.79.
- EV to Sales
- 1.20
- EV to EBITDA
- -38.60
- EV to Free Cash Flow
- -6.79
- EV to Operating Cash Flow
- -9.37
Balance Sheet
Orient Europharma Co., Ltd. has TWD 1.67B in cash and marketable securities with TWD 3.53B in debt, giving a net cash position of -TWD 1.86B billion.
- Cash & Marketable Securities
- TWD 1.67B
- Total Debt
- TWD 3.53B
- Net Cash
- -TWD 1.86B
- Net Cash Per Share
- -TWD 21.45
- Tangible Book Value Per Share
- TWD 72.49
Margins
Gross margin is 46.64%, with operating margin of -7.36%, and net profit margin of -11.58%.
- Gross Margin
- 46.64%
- Operating Margin
- -7.36%
- Pretax Margin
- -6.77%
- Net Profit Margin
- -11.58%
- EBITDA Margin
- -3.12%
- EBIT Margin
- -7.25%
Analyst Forecast
The average price target for Orient Europharma Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 3.77%
- EPS Growth Forecast
- -78.32%
